OncLive TV

Danielle K. DePalo, MD, discusses findings from a study comparing first-line isolated limb infusion/perfusion vs immune checkpoint inhibitors and intratumoral therapy in patients with surgically unresectable melanoma in-transit metastases.

Alessandro Santin, MD, discusses the clinical activity of sacituzumab govitecan-hziy in patients with recurrent endometrial cancer who overexpress Trop-2.

Andreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.

Lova L. Sun, MD, MSCE, discusses the association between duration of immunotherapy and overall survival in patients with advanced non–small-cell lung cancer.

Alexander I. Spira, MD, PhD, FACP, discusses the ongoing phase 3 PACIFIC-8 trial of durvalumab in combination with domvanalimab following concurrent chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer.

Joshua P. Sasine, MD, PhD, discusses the potential role of cilta-cel in earlier lines of therapy for patients with multiple myeloma.

David R. Oveisi, MD, discusses the evolution and potential role of bispecific antibodies in multiple myeloma, and presents several areas of unmet need regarding their use in this space.

Susan M. O’Brien, MD, discusses the use of pirtobrutinib for patients with hematologic malignancies who developed resistance to BTK inhibition.

Carolina D. Schinke, MD, discusses updated findings from the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

Ulka Nitin Vaishampayan, MBBS, discusses findings from the phase 3 CONTACT-03 trial in patients with renal cell carcinoma.

Bradley Monk, MD, FACS, FACOG, discusses findings from the phase 2 RAMP 201 trial in patients with low-grade serous ovarian cancer and the importance of these results within the context of the larger ovarian cancer treatment paradigm. 

James Chih-Hsin Yang, MD, discusses the investigation of pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous non–small cell lung cancer.

Guru P. Sonpavde, MD, discusses the potential impact of the phase 3 THOR study evaluating erdafitinib vs chemotherapy in patients with advanced or metastatic urothelial cancer harboring FGFR2/3 alterations.

Bruna Pellini, MD, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced non–small cell lung cancer treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel.

Marilyn Huang, MD, discusses the need for non-chemotherapy options in advanced ovarian cancer, as well as data on the use of neoadjuvant PARP inhibitors for this population in the phase 1 NOW study.

Suzanne B. Coopey, MD, FACS, discusses the benefits seen with the de-escalation of axillary lymph node surgery for patients with breast cancer, as well as current recommendations for the de-escalation or omission of this procedure.

Vincent K. Lam, MD, discusses findings from a study profiling the tumor immune microenvironment in patients with ALK fusion–positive lung cancer and potential future directions for this research.

Shubham Pant, MD, MBBS, discusses the background of the ongoing phase 2 RAGNAR trial evaluating the use of erdafitinib in patients with solid tumors harboring FGFR alterations.

George Lau, MD, FRCP, FAASLD, discusses the association between immune-related adverse effects and overall survival for patients with unresectable hepatocellular carcinoma enrolled on the phase 3 HIMALAYA trial.

Luis Paz-Ares, MD, PhD, discusses efficacy and safety findings from the phase 2 CARMEN-LC05 trial of tusamitamab ravtansine in patients with nonsquamous non–small cell lung cancer with CEACAM5 expression.

Funda Meric-Bernstam, MD, discusses a first-in-human phase 1/2 study of CBX-12 in patients with advanced or metastatic solid tumors.

Amir Fathi, MD, discusses findings from the phase 1b expansion portion of the phase 1/2 KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia harboring NPM1 mutations.

Jen-Jane Liu, MD, discusses how prostate-specific membrane antigen PET imaging may help inform lymph node dissection in the localized disease setting for patients with prostate cancer.

Toni Choueiri, MD, discusses remaining questions associated with the role of immune checkpoint inhibitor continuation following progression on a prior checkpoint blockade in advanced renal cell carcinoma, and attempts to address them through continued research.

Breelyn A. Wilky, MD, discusses the rationale for investigating the combination of zalifrelimab, balstilimab, and doxorubicin in patients with advanced/metastatic soft tissue sarcoma, and early results from a phase 2 trial.

Damon R. Reed, MD, discusses a phase 2 study of fam-trastuzumab deruxtecan-nxki in adolescent and young adult patients with recurrent HER2-positive osteosarcoma.

Joseph Christopher Murray, MD, PhD, discusses the investigation of peripheral myeloid cells as prognostic markers in patients with non–small cell lung cancer treated with cemiplimab.

Harry Gill, MD, FRCP, FRCPath, discusses updated efficacy data and analysis of genomic characteristics for ropeginterferon alfa-2B in primary myelofibrosis.

Shilpa Gupta, MD, discusses the design, methodology, and potential significance of the ongoing phase 3 MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma

Pedro Barata, MD, MSc, discusses the importance of the phase 3 EMBARK trial in patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.